A Survey of Insulin-Dependent Diabetes—Part I: Therapies and Devices by Takahashi, Daisuke et al.
Hindawi Publishing Corporation
International Journal of Telemedicine and Applications
Volume 2008, Article ID 639019, 15 pages
doi:10.1155/2008/639019
ReviewArticle
A Survey of Insulin-DependentDiabetes—Part I:
Therapies and Devices
Daisuke Takahashi,1 Yang Xiao,1 Fei Hu,2 and Michael Lewis2
1Department of Computer Science, The University of Alabama, Tuscaloosa, AL 35487-0290, USA
2Department of Computer Engineering, Rochester Institute of Technology, Rochester, NY 14623-5603, USA
Correspondence should be addressed to Yang Xiao, yangxiao@ieee.org
Received 17 August 2007; Accepted 14 November 2007
Recommended by Jelena Misic
Thispapersurveysdiabetestherapiesfromtelemedicineviewpoint.Intype1diabetestherapies,theexogenousinsulinreplacement
is generally considered as a primary treatment. However, the complete replacement of exogenous insulin is still a challenging
issue because of its complexity of modeling the dynamics, which is typically modeled nonlinearly. On the other hand, thanks to
the progress of medical devices, currently the diabetes therapies are being automated. These medical devices include automated
insulin pumps and blood glucose sensors. Insulin pumps are designed to create artiﬁcial insulin perfusion while they largely
rely on the blood glucose proﬁle measurements and these measurements are achieved by one or more blood glucose sensors.
The blood glucose measurements are also important for the insulin-dependent diabetes therapies. An insulin pump along with
sensorsestablishesagoodfeedbacksystemprovidingtheappropriateamountoftheexogenousinsulinondemand.Controllingthe
amount of exogenous insulin to suppress the blood glucose levels requires complicated computations. This paper mostly explains
both type 1 and 2 diabetes and their mechanisms accompanied by descriptions of diabetes therapy and medical devices currently
utilized in the therapy
Copyright © 2008 Daisuke Takahashi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Diabetes mellitus is a metabolic disorder resulting from the
permanent lack of insulin production from the pancreas
(type 1 diabetes) or the chronic degradation of the function-
ality of endogenous insulin (type 2 diabetes), which results
in raising the glucose concentration in blood because with-
out insulin, the cellular system cannot properly convert car-
bohydrates such as sugars, starches, or other foods into en-
ergy usable by the body. These factors eventually result in
severalcomplications,suchascardiovasculardisease,chronic
renalfailure,retinaldamage,nervedamage,andmicrovascu-
lar damage [1]. Both types 1 and 2 diabetes are chronic and
currently incurable, seemingly linked to genetics.
In addition, diabetes is a condition that disproportion-
ately aﬀects developed countries. From a report of the World
Health Organization (WHO), currently, around 180 mil-
lion people suﬀer from diabetes all over the world, and it is
thoughtthatover350millionpeoplewillsuﬀerfromdiabetes
bytheyear2030.Besides,thenumberofpeoplediedfromdi-
abetes was approximately 1.1 million in 2005, and half of this
number is aged under 70 years old [2]. It is also thought that
136 billion dollars are spent annually in the United States for
12 million diabetes patients [3, 4].
Currenttreatmentfordiabetescanincludehome-admin-
istered care under the guidance of a physician. Intensive
treatment can mitigate the eﬀects of existing conditions as
well as reducing the risk of developing advanced complica-
tions, such as those previously listed.
Early methods of home care involved using logs and ta-
bles, applying diet and exercise to predetermined doses pre-
scribed by the patient’s doctor. Modern microcontrollers,
sensors, and pumps now allow for the automated adminis-
tration of insulin within doctor-prescribed parameters. Fur-
ther, technological advances currently permit these devices
to be wearable, acting as an artiﬁcial pancreas. The goals of
such a product include being safe, automatic, and nonintru-
sive. These devices must employ an eﬀective control scheme
that allows the blood glucose (BG) level to be kept within a
safe range of nominal.2 International Journal of Telemedicine and Applications
This paper overviews diabetes therapies and devices
from a telemedicine viewpoint. We mostly discuss the
insulin-dependent diabetes therapy or type 1 diabetic ther-
apy although we may occasionally mention the noninsulin-
dependent one. It ﬁrst briefs both types of diabetes mellitus
with respect to the mechanisms of endogenous insulin de-
ﬁciency in Section 2.I nSection 3, we outline a basic proce-
dure of the therapy and address the diﬃculties and the goals.
In Section 4, we survey several ways, in which the exogenous
insulin is injected, and their eﬀect. In Section 5,w ep r e s e n t
some commercially available medical devices particularly for
diabetes as well as those in research. Then Section 6 is spent
to brieﬂy explain control theories used for the diabetes ther-
apy. Due to the limit space and complexity of controlling the
amount of exogenous insulin to suppress the blood glucose
levels, control methods are brieﬂy discussed. Details about
the control schemes are included in another paper [5]. Fi-
nally, we conclude our paper in Section 7.
2. DIABETES MELLITUS
Diabetes has been recognized since about 2000 B.C. How-
ever,untilthediscoveryofinsulinin1921,diabeteswasprop-
erly treated so that the insulin-dependent diabetic could de-
lay the emergence of the complications [6, 7]. A characteris-
tic of diabetes mellitus is the high blood glucose concentra-
tionmainlycausedbythelackofinternalinsulinproduction,
which is the principal hormone and suppresses the rising of
thebloodglucoseconcentrationbyturningitintoamainen-
ergy required by the human body [1]. While blood glucose is
used as energy to work muscles, the brain, and all other tis-
sues,excessiveconcentrationofglucoseinbloodleadstosev-
eralcomplications.Cardiovasculardisease,chronicrenalfail-
ure, retinal damage, nerve damage, and microvascular dam-
age are known as serious complications caused by diabetes.
According to mechanisms in which insulin deﬁciency oc-
curs, the World Health Organization categorizes two types of
diabetes mellitus: type 1 and type 2 diabetes [1]. The charac-
teristics of type 1 diabetes are the permanent lack of insulin
production from the pancreas due to the destruction of the β
cells of the Islets of Langerhans. In this kind of diabetes, in-
sulin replacement is required to compensate its production
by the therapy.
On the other hand, in type 2 diabetes, the function-
ality of internal insulin becomes gradually degraded, and
metabolisms that exchange blood glucose into a main en-
ergy work less than that in the normal person. This condi-
tion keeps blood glucose unused and eventually leads to hy-
perglycemia, which may cause eye, kidney, and nerve dam-
age [8]. In the early stage, exercises and controlled regimens
can improve, but not cure, this metabolic disorder. However,
leaving type 2 diabetes untreated, hyperglycemia requires ex-
ogenous insulin inputs like the type 1 diabetic therapy.
2.1. Bloodglucoseandinsulin
From its metabolism, blood glucose or blood sugar derived
from a form of carbohydrate eventually turns into energy re-
quired by the human body and also works the brain and the
nervous system. Glucose is typically carried throughout the
human body via blood vessels as a form of red blood cell and
plasma. In the human body, only insulin and glucagon play
ar o l eo fr e g u l a t i n gb l o o dg l u c o s el e v e l sw i t h i nav e r yn a r -
row range by bearing it from blood to the most cells, such as
muscles and adipose tissues, turning it to energy [8, 9].
Typically, either excess or shortage of glucose in blood
is known as a metabolic disorder. The condition where the
blood glucose is much lower than expected is called hypo-
glycemia causing drowsiness, mental malfunctioning, irri-
tability, and loss of consciousness [8]. To the contrary, the
condition where the blood glucose levels are much higher is
called hyperglycemia, and long-term hyperglycemic condi-
tions eventually result in diabetes [8].
As we already mentioned, insulin strictly regulates blood
glucose levels. Insulin is a polypeptide hormone and a pro-
duction of the β cells of the Islets of Langerhans in the pan-
creas. The main activities of endogenous insulin are mainly
two things: to help the liver yield glycogen to be preserved
from glucose, and to help muscles and adipose tissues intake
glucose to be broken down into energy. However, the lack of
insulin in the liver forces glycogen to turn back to glucose
that is ejected into blood vessels. Also, the condition leads to
keep glucose in blood not processed into energy. Thus the
lack or the shortage of the insulin production by the pan-
creas immediately causes metabolic disorders, that is, hyper-
glycemia or high blood glucose concentration, thus eventu-
ally resulting in diabetes [9].
2.2. Type1diabetes
In type 1 diabetes, the β cells in the pancreas are destroyed
by the immune system which should respond to an infec-
tion caused by viruses, such as the Coxsackie virus family or
German measles [10]. As a result, the pancreas stops sup-
plying insulin into blood causing high blood glucose con-
centration. Although type 1 diabetes is occasionally called
childhood, juvenile, or insulin-dependent diabetes, it is not
a metabolic disorder that emerges only during a childhood
but after growing up to adults [10].
Whentype1diabetesisuntreatedforalongtime,iteven-
tuallyresultsindiabeticcoma,diabeticketoacidosis,ordeath
[10]. Diabetic ketoacidosis comes from a fact that when
blood glucose cannot be used in a form of energy for the
body due to the lack of insulin, instead, proteins or fats are
used to be turned into a main energy. This metabolic pro-
cess involves several chemical reactions, such as oxidization
of the fatty acid resulting into acetyl coenzyme A (CoA), and
a sequence of the citric acid cycle and the respiratory chain
where acetyl coenzyme is eventually turned into energy by
an electron transport chain [11–14]. However, the process of
these chemical reactions also creates ketones as by-products,
and because of their acidity, ketones turn blood into acid re-
sulting in acidosis or ketoacidosis.
Treatment of type 1 diabetes is to compensate for the
loss of endogenous insulin usually by infusing exogenous in-
sulin into the body. This artiﬁcial insulin supplement sup-
presses a rise of blood glucose concentration and delivers
blood glucose to the most cells through the body. The insulinDaisuke Takahashi et al. 3
injections are conducted three or four times per day, or alter-
natively, an insulin pump is utilized to continuously deliver
a little fast-acting insulin for the basal insulin supply [15].
These treatments of type 1 diabetes are known as the insulin-
dependent diabetes therapy.
2.3. Type2diabetes
Type 2 diabetes emerges in conditions of insulin resistance,
insulin deﬁciency, and hyperglycemia [16]. In insulin re-
sistance, since functions of internal insulin are largely de-
graded, it cannot appropriately facilitate the insulin-glucose
metabolism, so regardless of its existence, body cells cannot
take in blood glucose enough for energy supply [17]. Even-
tually, type 2 diabetes stimulates hyperglycemia, which is a
condition where blood glucose levels keep much higher than
expected for a long time, it may cause eye, kidney, and nerve
damage [8]. However, in its initial stages, the symptoms of
the disease are not so serious that they cannot be often real-
ized until they are brought up to a more critical and chronic
situation [17]. Type 2 diabetes is mainly caused by several
irregular lifestyles, such as the lack of exercise, obesity, or a
sedentarylifestyle[16].Meanwhile,geneticfactorsalsocause
this type of diabetes.
Type2 diabetes is also callednoninsulin-dependent, obe-
sity related, or adult-onset diabetes.
Treatment in the earlier phases of type 2 diabetes is com-
paratively easier than type 1 diabetes because of the existence
of more or less internal insulin production [17]. The treat-
ment in the initial stages mainly consists of glycemic con-
t r o l ,w h i c hk e e p sb l o o dg l u c o s el e v e l sn o r m a lt op r e v e n th y -
perglycemic stimuli [18], and lifestyle control, which pro-
vides patients with desired meals and exercises from the as-
pect of the personal nutrition, and typically supported by a
variety of medical staﬀs[ 17]. However, as type 2 diabetes
growsworse,theantidiabeticdrugtherapyisnecessaryinad-
dition to glycemic and lifestyle controls. Moreover, if these
therapies cannot help managing blood glucose levels, further
treatments, such as insulin therapy, are required besides the
oral medication therapy.
Thereasonororiginoftype2diabetesisstillunknownin
etiology, and currently, no one can be cured completely from
type 2 diabetes [17].
3. INSULIN-DEPENDENT DIABETES THERAPY
A basic idea of insulin-dependent diabetes therapy is initi-
ated by a report of the Diabetes Control and Complication
Trial, that is, the well-controlled glucose metabolism man-
ages well or delays the emergence of the complications of
insulin-dependent diabetes [15, 19, 20]. Thus in typical cases
of the insulin therapy, according to blood tests, three or four
timesofinsulininjectionsaresubcutaneouslycarriedoutper
day to compensate the lack of endogenous insulin secretion
for type 1 diabetes in order to suppress the rise of blood glu-
cose levels [10]. Sample blood is typically picked from the
tip of a ﬁnger or earlobe, and the amount of blood glucose
is checked using a sensor [15]. For example, thanks to the
development of the NPH (neutral protamine hagedorn) in-
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Figure 1: An example of insulin pump that integrates a blood glu-
cose sensor [21]. Patient’s blood is sampled from the tip of his/her
ﬁnger, and from the direct measurements of a blood glucose sensor,
the amount of the short-acting insulin is adjusted and continuously
delivered into the human body.
sulin, the combination of the NPH and regular insulin is in-
jected before breakfast. Usually, the eﬀect of the NPH insulin
is very slowandcontinues foralong period, whichresembles
the basal supply of endogenous insulin for a normal person.
Meanwhile, the regular insulin makes up for the bolus sup-
ply of endogenous insulin during a meal intake, so the reg-
ular insulin acts immediately and whose peak is higher than
the NPH insulin, shown in Figure 1. Then before dinner and
bedtime, a couple of other regular insulin injections are car-
ried out according to test results [6].
Although the subcutaneous insulin infusion is expected
to follow precisely the complex real hormone secretion, the
conventional insulin therapy does not follow this complex
system enough neither temporally nor quantitatively yet. In
fact, the metabolism of a nondiabetes person controls blood
glucose levels in a quite narrow range all the time [6], for
example, within the range of 4 to 8mmol/L [22].
Thus one goal of the insulin-dependent diabetes ther-
apy is to precisely capture the insulin-glucose dynamics of
the normal person and design a system yielding the insulin
secretion quantitatively as close to the real metabolism as
possible. However, in practice, many parameters around the
metabolism, such as environmental conditions, stress of pa-
tients, behavioral changes, and duration of tests make a cal-
culation of the actual demand of exogenous insulin intricate
[23]. As a result, designed algorithms and mathematical rep-
resentations must be complex and nonlinearly modeled in
order to resemble the real hormone secretion [24].
Meanwhile, to support the therapy, short-term in vivo
glucose sensors have been recently integrated into insulin-
dependent diabetes therapeutic system [25]. The in vivo glu-
cosesensorstypicallyareimplantedsubcutaneouslyandsend4 International Journal of Telemedicine and Applications
blood glucose proﬁles as vital signals to exterior receivers,
such as PDAs or laptop PCs, at very short intervals. Since
many samples make modeling a blood glucose curve rela-
tively easy resulting in enhancing predictions of the future
transition of blood glucose concentration [24], the in vivo
sensors are considered to be largely beneﬁcial to a reliable
insulin-dependent diabetes therapy. Currently in collabora-
tion with an insulin pump, in vivo blood glucose sensors are
integrated into closed-loop blood glucose control systems.
Problems of current in vivo blood glucose sensors are,
however, that reliable long-term blood glucose monitoring is
still challenging and is not approved by U.S. Food and Drug
Administration (FDA). Currently, only three-day monitor-
ing is considered to be safe and reliable [24, 26]. In addition,
these blood glucose sensors largely still rely on the discrete
measurements rather than continuous ones [24].
Broadly speaking, as types of the insulin therapy, three
models are mainly utilized, for example, open-loop, closed-
loop, and partially closed-loop control models. These mod-
els have their own advantages and disadvantages for their
use. Among the three models, the open-loop control and the
partial closed-loop control require physician’s assistance for
injecting the exogenous insulin, whereas in the closed-loop
control according to feedbacks from the output of blood glu-
cose sensors, the amount of the exogenous insulin is deter-
mined so that the system is ideally autonomous and self-
organized. Examples of the closed-loop control schemes are
pole-assignment strategy and self-tuning adaptive control,
and examples of the partially closed-loop controls are the
automated insulin dosage advisor (AIDA) and the diabetes
advisory system (DIAS) [15].
4. METHODS OF INSULIN INJECTION AND INFUSION
There are several ways to inject insulin into the human
body, that is, intravenous, subcutaneous, and intraperitoneal
routes. The most direct method is intravenous infusion [15],
while subtler ways can be used for continuous or less painful
dispensation, such as subcutaneous injection. Furthermore,
the method of injection as well as the control method places
a number of requirements on the type of insulin applied to
the patient. In either way of the insulin infusion, the objec-
tive is to keep the condition of normoglycemia for the type 1
diabetic like normal people at all times.
4.1. Intravenousinsulininjection
One way for the exogenous insulin injection is to utilize
an intravenous route. Intravenous infusion works by in-
jecting drugs directly into a patient’s blood stream through
a needle, which penetrates the skin, and into a vein. Sev-
eral advantages of the intravenous insulin injection bene-
ﬁt for insulin-dependent diabetes therapy. Compared with
the other routes, to inject insulin intravenously delivers in-
sulin more quickly and helps it reach the bloodstream in the
higher ratio. In addition, against the overdose of insulin, uti-
lizing this route can enhance the sensitivity to hypoglycemia,
respond immediately and stop delivering. Furthermore, this
route of insulin injection is considered to be better suited for
improved closed-loop mechanisms [27].
However, despite of a lot of beneﬁts, the intravenous
route also includes a couple of shortcomings. For example,
in the intravenous insulin infusion, since the catheter is kept
to be put into the vein, this may cause the blood vessel to be
irritated. Also, in a long time insulin infusion, the catheter
may be put away from the vein or it may be obstructed [27].
One experiment showed that for the type 1 diabetic, a
continuous crystalline insulin infusion intravenously could
improve the insulin proﬁle prominently close to the nor-
mal for 30 minutes from the beginning of a meal [6]. To the
contrary, the same experiment reported the anomaly of the
glycemic proﬁle where the blood glucose concentration re-
gained above normal after the initial 15–30 minutes of the
experiment [6].
Moreover, to achieve the normalization of the glycemic
and metabolic proﬁle with an ambulatory insulin-dependent
diabetes therapy, delivering insulin in the central venous
route with a continuous open-loop infusion system is fea-
sible [28].
4.2. Subcutaneousinsulininjection
An alternative way to inject exogenous insulin is the subcu-
taneous route that is much simpler and less risky of infection
at an injection site than in an intravenous route, although
it presents certain design challenges for blood glucose level
control. It can be used to facilitate continuous, noninter-
rupted glucose management. Due to its relatively pain-free
application (compared to intravenous infusion), it is much
more agreeable to home monitoring patients who wear ar-
tiﬁcial pancreas devices at all times [29]. Therefore, basi-
cally insulin injections and infusions are conducted safely by
the diabetic on their own. Most of the clinical experiments
demonstrated that, compared with conventional single in-
jections, to infuse insulin subcutaneously administrates the
glycemic proﬁle better. Also, it was turned out that by deliv-
ering insulin mechanically, long-term subcutaneous experi-
ments regulated values of hemoglobin A1C for the diabetic
[6].
However, occasionally infusing insulin subcutaneously is
not suﬃcient for reversing diabetic complications, particu-
larly brittle patients, because of its limitations of controlling
the glycemic proﬁle [6].
4.3. Intraperitonealinsulininjection
Although only a limited number of experiments were carried
out, insulin can be injected in an intraperoneal route. Early
experiments of insulin-dependent diabetes therapy with the
intraperitoneal insulin infusion showed that insulin soaked
up from the peritoneum would appear in the surrounding
blood system of the diabetic with peritoneal dialysis. Mean-
while, it was possible for diabetics to have daily activities and
ambulate as usual. In addition to these beneﬁts, the same ex-
periments demonstrated no diabetic complications by daily
basis catheters replacement [6, 30].Daisuke Takahashi et al. 5
Furthermore, in the intraperitoneal insulin infusion, in-
sulin is soaked up into the blood system moderately in the
range of subcutaneous insulin injection to intravenous in-
sulin infusion, while the insulin is delivered from the peri-
toneum directly to the liver resulting in the reduction of high
concentration of peripheral insulin [6].
On the other hand, despite of its advantages, in the in-
traperitoneal insulin infusion, external insulin delivery sys-
tems increase the risk of infection developing peritonitis as
well as tissue degradation at the catheter site [6].
4.4. Comparisonofmethods
Because it is less invasive to the body, subcutaneous injec-
tion is generally safer for several reasons [15]. Persons with
an active lifestyle are put at risk by leaving an embedded
needle protruding from their body, necessary to bridge the
ﬂuids gap between their bodies and their artiﬁcial pancreas.
Subcutaneous administration greatly reduces this safety haz-
ard by interfacing no deeper than the skin layers, often dis-
tributed over an area, decreasing the invasiveness of the de-
vice [29]. Furthermore, continuous needle-sticking as well
as prolonged embedding poses health risks of infection, clot-
ting, or other sorts of body-triggered rejection to an invasive
foreign device. Because subcutaneous injection is far less in-
vasive, it is less likely to trigger self-defense mechanisms like
this, and if triggered, they tend to be far less severe.
However,subcutaneousinjectionisnotwithoutitsdraw-
backs. Due to its less invasive nature, insulin takes far longer
to permeate into the body than through direct intravenous
infusion. It has been reported that when using standard in-
sulin for both injection types, subcutaneous injection can
take as much as three times longer to take eﬀect. This makes
implementing an accurate control system quite challenging
due to the time delays.
4.5. Insulinselection
Several options are available for insulin to be injected, de-
pending upon the situation [15]. Regular insulin has histor-
ically been used to treat diabetes. It can be both intravenous
andsubcutaneousinjected,dependingupontheinjectionin-
terface used. When it is subcutaneously injected, its eﬀects
take up to three times longer than if it is intravenously in-
jected, posing a diﬃcult control systems problem.
An insulin preparation by the name of Lispro was de-
veloped to aid in the rapid absorption of the insulin [15].
It is designed to take immediate eﬀect, and can be fully ab-
sorbed into the body’s system signiﬁcantly faster than regu-
lar insulin. Lispro is designed to take eﬀect within 15 min-
utes and peak about an hour after application. Because of its
fast-delivery capabilities, Lispro is the most commonly used
with subcutaneous injection. Subcutaneous injected Lispro
h a sb e e np r o v e nt ot a k ee ﬀect within approximately the same
time frame as intravenous injected normal insulin. This en-
ables home monitoring and injection patients to control
their glucose levels to the same levels as with intravenous
management, but in a far less invasive and painful way.
An insulin preparation by the name of NPH has also
beendevelopedfortheexactoppositepurposeofLispro[15].
NPH is designed to take eﬀect over a much longer period of
time, lasting up to 24 hours. The purpose of insulin with this
property is to provide the patient with a predictable base-
line level of insulin throughout the day, allowing the con-
trol system to focus its eﬀorts on accounting for and correct-
ing anomalies and disruptions that are encountered, such as
meals, exercise, and sleep.
Appropriate injections of a combination of Lispro and
NPH has been proven incredibly eﬀective in maintaining
short and long-term glucose stability within patients using
a continuous monitoring and control device [29]. Lispro is
usually used for fast-acting control to counterbalance blood
glucose ﬂuctuations due to meals. NPH is usually used to
provide a constant trickle of insulin in order to establish a
baseline, known as a basal level.
5. DEVICES IN INSULIN-DEPENDENT
DIABETES THERAPY
5.1. Insulinpump
Insulin pumps are used to create an artiﬁcial insulin secre-
tion subcutaneously that can suppress excessive blood glu-
cose propagation for the type 1 diabetic. In general, it con-
tinuously delivers a basal rate of exogenous insulin automat-
ically and also has capability of manually adding extra in-
sulin to the basal rate for the intensive insulin secretion by a
continuous subcutaneous insulin infusion (CSII) technique
[31]. Most of the insulin pumps consist of a small processing
module with a display, a disposable insulin reservoir, and an
insulin syringe, and are powered by batteries, illustrated in
Figures 2 and 3. The amount of insulin supply is externally
controllable depending on blood glucose measurements.
In the use of an insulin pump, after ﬁnishing setting-up,
a patient inserts a cannula into his/her abdomen as seen in
Figure 2. Upon determining an insulin infusion rate, it starts
delivering exogenous insulin continuously in 24 hours per
day and 7 days a week, that is, a basal dose [32]. During
meal time, when more amount of the insulin dosage is re-
quired because of carbohydrate intakes, the insulin pump
enhances its insulin supply to adjust high blood glucose con-
centrations, which is called a bolus dose so that this artiﬁ-
cial insulin metabolism should occur after a real physiologi-
cal metabolism in the normal human body.
In case of the insulin injection using a syringe, since the
insulin dosage is performed three or four times a day, each
shot is devised in such a way that the insulin dosage can keep
its eﬀect constantly as long as possible. In general, using a
delayed action insulin or slow-acting insulin helps a basal
supply of exogenous insulin. A diﬃculty of the insulin in-
jection, however, results from using this slow-acting insulin.
Although the duration of the eﬀect is achieved longer than
other types of insulin, it also takes a longer time to start tak-
ing eﬀect as illustrated in Figure 1. This disadvantage largely
prevents eﬀective predictions of a future blood glucose pro-
ﬁle. In this connection, its variance eventually grows up to
52% [31]. Moreover, the insulin injection with insulin shots6 International Journal of Telemedicine and Applications
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Figure 2: An image of an insulin pump. This image also includes a
blood glucose sensor. In the general use, an insulin pump continu-
ously infuses a little amount of the short-acting exogenous insulin
via an attached needle as a basal dosage. It is also able to add extra
exogenousinsulinforintensivecare,forexample,mealtime.Insulin
pumps have a lot of advantages compared with the insulin shots.
Model 515
Model 715
Figure 3: Another example of insulin pumps of Medtronic. A pro-
cessing module has a small display that shows a current rate of an
exogenous insulin infusion. It also has several control buttons just
belowthedisplay.Twoofthesebuttonsareusedtomanageacurrent
insulin infusion rate.
inevitably restricts a patient’s life style, for example, the hour
of rising and meals.
Meanwhile, in case of insulin pumps, an accompanying
insulin cannula is put into the human body continuously
supplying a little amount of the short-acting insulin even in
bedtime.Althoughthedurationoftheeﬀectofinsulinisvery
low, the short-acting insulin acts faster than the slow-acting
insulin. Therefore, a little amount of a continuous dose of
insulin can make predictions of blood glucose concentration
comparativelyeasyanditsvarianceisnotmorethan3%[31].
Currently, one of the most promising pump technologies
is a piezoelectric ﬂuid device [29]. Piezoelectric pumps oper-
Sensor
Controller
Micro-needle array
Insulin
reservoir
Membrane
Piezoelectric
pump
Figure 4: Piezoelectric pump and micro-needle device.
atebyapplyingvoltagetoathinleadzirconatetitanate(PZT)
ﬁlm. This distorts the ﬁlm, causing it to pump ﬂuid through
an adjoined silicon nitride membrane, shown in Figure 4.
The displacement volume of an unloaded pump can be
described as
ΔV =
3r4(5+2μ)(1 −μ)d13U
4h2(3+2μ)
, (1)
K =
3r4(5+2μ)(1 −μ)d13
4h2(3+2μ)
, (2)
ΔV = KΔU, (3)
Q = KfΔU, (4)
where r is the radius of the membrane in μm, h is the thick-
ness of the membrane in μm, μ is the Poisson ratio, ΔU is
the peak-to-peak voltage applied to the pump every period,
d13 is the piezoelectric coeﬃcient, and f is the frequency at
which voltage is applied to the pump. K represents the pump
coeﬃcient described by (1). Q is the ﬂow rate of the pump.
Note that ΔV is linearly proportional to ΔU. Likewise, Q
is also linear for a ﬁxed f or a ﬁxed ΔU. This permits very
simple and intuitive control of the pump by the controller,
allowing it to control the ﬂow rate through a variable ampli-
tude signal or a variable frequency signal, depending upon
system requirements and the resources available.
Pump reliability is an incredibly crucial factor when con-
sidering a blood glucose management system. Pump, sensor,
or control failure can lead to incorrect dosages or even a fail-
ure to inject. Due to its mechanical nature, pump failure is
often the most likely cause of malfunction. This can results
from o-ring leaks, air bubbles, bleeding, infection, and clogs.
These conditions can easily result in hyperglycemia or hypo-
glycemia and must be monitored for.
We compare ﬁve types of popular insulin pumps in
Table 1.
5.2. Bloodglucosesensor
In consideration of easy predictions of blood glucose pro-
ﬁle, recently, utilization of both an insulin pump and a blood
glucose sensor is very important for the intensive insulin-
dependent diabetes therapy. In general, when the system has
a capability of the continuous glucose measurement, andDaisuke Takahashi et al. 7
Table 1: Speciﬁcation comparison of commercial insulin pumps.
Company Animas Deltec Disetronic MiniMed Insulet
Model IR-1250 [11]C o z m o [ 12] Spirit [13] Paradigm 522/722
[14] OmniPod [33]
Dimensions 79 × 51 × 19 80 × 47 × 24 80 × 56 × 20 522: 51 × 79 × 20
722: 51 × 79 × 20
Pod: 41 × 61 × 18
Pda: 66 × 110 × 26
Screen size 992sqmm 870sqmm Unavailable 774sqmm 1,848sqmm on PDA
controller
Basal
delivery Every 3 minutes Every 3 minutes Every 3 minutes Varies Information
unavailable
Basal
temperature
Initially −90% to
+200%, varies for
every half an hour
Varies from 0% to
200% with an
increment of 5%
for every half an
hour
Varies from 0% to
200% with an
increment of 10%
for every half an
hour
+/−0.1 increment
as single basal rate
for 0.5 to 24 hours
Information
unavailable
Carb and
correction
factors
Manual entry and
assist from EZ
manager
Manual
carbohydrate, BG
from attached
CoZ monitor
Manual
carbohydrate, BG
from Accu-check
BG monitor
Manual
carbohydrate, BG
from BD meter or
manual entry
Information
unavailable
Battery AA lithium × 1 AAA × 1 AA × 1 Alkaline
or Rechargeable AAA AAA × 2
M o t o r D CD CD CD CS t e p p e r
Memory
Nonvolatile: 600
bolus, 270 basal,
120 daily totals, 30
alarms, and 60
primes
Nonvolatile: 90
days of basals,
carbohydrates,
boluses,
correction
boluses, and
alarms
Nonvolatile: 90
days history recall
of last 30 boluses,
alerts, daily
insulin totals, and
temporary basal
rate increase
4000 events
volatile: 24
boluses, and 7
days totals
90 days of data
Extra
features
Clip-on covers,
personalized
carbohydrate, and
correction factors,
tracks residual
bolus insulin
Carbohydrate and
correction factors,
tracks residual
bolus insulin,
detailed records of
pump, and daily
bolus total
correction
Availability of
diﬀerent types of
user menus, icon
and menu driven
programming,
backlight display,
and reversible
display screen
Extended bolus,
auto oﬀ
Integrated free style
meter, 1000 common
foods in PDA
with this measurement, a rate of exogenous insulin dosage is
automatically or manually adjusted, and the system is called
a closed-loop control system. In this system, a glucose sensor
may be implanted in the human body as shown in Figure 5
[15]. On the other hand, when the system still counts on
periodical glucose measurements, the system is called a par-
tiallyclosed-loopcontrolsystem.Generally,thislattersystem
utilizes very complex nonlinear calculations or mathematical
modeling to pursue its accuracy from few glucose measure-
ments.Besides,insulindosageplanisdesignedbyaphysician
with an expert system that performs comparisons between
the generated predictions and model cases.
5.2.1. Fingersticks
There are many kinds of blood glucose sensors to be ex-
ploited. One of them, ﬁngerstick meter readings, measures
blood glucose proﬁles directly from blood samples taken out
ofthetipofaﬁnger.Thisisinvasiveandcanbepainful.Addi-
tionally, measurements of this sort are only taken a few times
per day due to the conscious eﬀort required to perform them
[34].
In testing a patient blood sample, for example [35], some
products require only 0.3 micro liters of the blood sample,
but required samplings are at least 4 times per day [36]. Be-
sides, this kind of sensor is also integrated into an insulin
pumpenhancingportabilityofthesystemaswellaseliminat-
ingarequirementofthemanualinputofdataintotheinsulin
pump, shown in Figure 6 [35]. A drawback of the sensor is
that since it invasively samples blood from a ﬁnger or ear-
lobe, it is almost impossible to take samples continuously in
order to enhance the measurements. Therefore, increasingly,
diﬀerent types of sensors are being developed and used, and
they provide a wealth of beneﬁts compared to ﬁnger sticks.
5.2.2. Implantablesensors
In addition to the ﬁngerstick meter readings, implantable
glucose sensors are available with some limitations. One
type of these implantable sensors is needle-type sensors8 International Journal of Telemedicine and Applications
Figure 5: An image shows a miniature size of in vivo blood glu-
cose sensor that is being developed [15]. It is currently proven by
FDA that in vivo blood glucose sensors are only safe and reliable
in a short period of time (e.g., three days). Thus after the period,
they are required to be replaced by a new one regularly to keep their
accuracy.
Figure 6: An image shows a ﬁngerstick meter reading. In the use of
the sensor, ﬁrst oﬀ, cut the tip of a ﬁnger or earlobe bleeding. Then
put the blood on a blood glucose sensor, which is a protuberance at
the bottom of the module. The result is shown on the display in the
middle-top of the module.
[24]. These needle-type sensors are intravenously or subcu-
taneously inserted into the body. Intravenous systems mon-
itor blood glucose levels by drawing blood through a vascu-
larly embedded needle [15]. This has the advantage of up to
date, real-time BG levels, but at the expensive of being inva-
sive and painful. Additionally, there are long term eﬀects as-
sociated with prolonged vascular invasion, making it a sub-
optimal solution for continuous long-term home monitor-
ing.
Subcutaneous glucose sensors are small electrode devices
that can be inserted into the skin in the fatty tissues. This
includes collecting a blood sample from the dermis layer of
the skin [24], which is located about a tenth of a millime-
ter into the surface of the body [2]. When the sensors are
placed correctly, current proportional to the blood glucose
level can be detected and measured. For example, a probe
of a subcutaneous sensor is made of an amperometric cell
covered by a thin membrane. With this sensor, only needle
part is inserted subcutaneously into the body while a proces-
sor module stays outside. Due to its shallow position, sub-
cutaneous monitoring can be signiﬁcantly less painful than
ﬁnger sticking. The greatest boon of subcutaneous monitor-
ing, however, is that it can be performed continuously in a
wearable fashion. This quality enables new types of control
techniques to be exploited. The ﬁner the measuring time in-
crement is, the more accurate control methods will be. Con-
tinuously glucose monitoring permits real-time signal ﬁlter-
ing in attempts to closely regulate changes in glucose due to
various factors such as meals, exercise, or sleep patterns.
There are several methods for administering subcuta-
neous monitoring, including dialysis and open-ﬂow microp-
erfusion. Currently, the most advanced method of subcuta-
neous monitoring is considered to be microperfusion [24].
Microperfusion entails diﬀusing interstitial ﬂuids from the
dermis into a double lumen catheter where it can be moni-
tored by an external sensor without actually drawing blood.
Also, another type of in vivo sensor is a small piece of
module which is completely implanted into a segment of
the body of the diabetic. Since these glucose sensors are im-
planted into the human body, continuous measurement of
blood glucose levels will be possible. The authors in [26]
demonstrated that samplings were conducted every 5 min-
utes. The sampled blood glucose proﬁles are wirelessly trans-
mitted to external receivers that could be a PDA or some
othersmalldeviceslookinglikealist-watch.Accordingtothe
transferred vital data, it is preferable to automatically recon-
ﬁgure a current insulin delivery rate, but some systems still
require the users to manually reconﬁgure the delivery rate.
Although, if realized, the continuously blood glucose moni-
toring must largely beneﬁt for the insulin therapy, there are
many diﬃculties to implant blood sensors subcutaneously in
a long period of time because of physiological reactions that
deteriorate the sensors and limit them working suﬃciently
u pt o3d a y s[ 21, 24, 37]. For example, MiniMed CGSM Sys-
tem Gold is currently approved by U.S. Food and Drug Ad-
ministration (FDA) for 3-day use [24, 26].
5.2.3. GlucoWatch
Furthermore, noninvasive blood glucose sensors also exist.
Dielectric spectroscopy (DS) is a noninvasive, extracorporeal
approach to continuous blood glucose monitoring [2, 24].
DS involves analyzing the electrolytebalance across cells, and
comparing those results to known behaviors for diﬀering
BG concentrations. One implementation of DS blood glu-
cose monitoring entails coupling an open resonant circuit
to the skin. This acts as an RCL sensor (R refers to a gen-
eral organic molecule and CL refers to chlorine), comparing
measurement results to derived system models in order to
deduct the BG level of the patient.
GlucoWatch is a new glucose monitor from Cygnus
Corp., Ill,USA.Themonitorstrapstothewristofthepatient
and uses a patented electrochemical sensor to measure glu-
cose levels in the patient. The GlucoWatch works both con-
tinuously and noninvasively, permitting closed loop blood
glucose level control. GlucoWatch displays the most recent
blood glucose levels of the patient, updating every 20 min-
utes, and will sound an alarm if the blood sugar level goes
above or below predetermined thresholds. The device stores
the previous 4,000 readings that can be oﬄoaded for use byDaisuke Takahashi et al. 9
a physician. This permits accurate monitoring of long-term
insulin dosage regiments and their results.
TheGlucoWatchhasalsorecentlywonFDAapprovaland
is oﬀered for sale in the United States and the UK. The de-
vice is actually based upon technology that is almost 100
years old. It takes advantage of the observation that an elec-
tric current can selectively transport chemicals through hu-
man skin. This transport phenomenon, called iontophoresis,
has historically been seen as a one-way street, a way to get
chemicals into the body. Cygnus scientists and engineers saw
an untapped opportunity, creating a device that reverses ion-
tophoresis to get the glucose out. “Al o to fs u b s t a n c e sc a nb e
measured through reverse iontophoresis, but we felt there was
a great unmet need for glucose monitoring,” says Dr. Russell
Potts, a biochemist and Cygnus vice president of research
[38].
The watch applies a biosensor, called the Autosensor,
against the skin that measures BG levels, producing a cur-
rent proportional to the BG level. A 20-minute analysis cycle
starts as the sensor silver-silver chloride iontophoresis elec-
trode applies a 300-microamp current to the skin. For the
next three minutes, positive and negative ions travel through
the patient skin to the GlucoWatch side-by-side collection
discs, which serve as an anode and cathode during glucose
extraction.Thisionmigrationactsasaglucosetransport,de-
positing it at the cathode to be measured. The onboard mi-
crocontroller then interprets the glucose level into a standard
unit of mm/dl.
The DirecNet group conducted a 6-month randomized
trial[4]tomeasuretheeﬀectsoftheGlucoWatchcontinuous
sensor on blood glucose control, hypoglycemia, and quality
oflifeascomparedtostandardcare.Attheendofsixmonths,
t h e r ew a sn om e a s u r a b l ed i ﬀerence in blood glucose control
between the experimental and control groups, as measured
by A1C and mean glucose using the Medtronic retrospective
CGMS device. The results also showed that the use of the de-
vice had no positive or negative psychological impact on the
subjects in the experimental group. These results were puz-
zling until the usage data was reviewed, which tracked the
number of times per week subjects actually used the device.
During the ﬁrst month, 64% of subjects used the device at
leasttwiceperweek(2.1±0.8).However,bythethirdmonth,
average use was only 1.6 ± 0.7timesperweek,and7ofthe99
subjectshaddiscontinuedusealtogether.Bythesixthmonth,
the average use was 1.5 ± 0.6 times per week, and 26 of the
original 99 subjects had discontinued use. In summary, dif-
ferences in clinical outcome failed to materialize because an
increasingnumberofsubjectsstoppedusingthedevice.Data
gathered from the questionnaires revealed that families felt
the information gained from the device was not worth the
discomfort and adhesive problems encountered with its use.
The current version of GlucoWatch, called GlucoWatch
G2 Biographer, is shown in Figure 7 [1]. As already men-
tioned, a list-watch shaped blood glucose sensor utilizes a
quite low electric current to draw blood glucose penetra-
ble through the skin [1]. This collected glucose is aggregated
into a sensing part of the device integrating an electrode that
is used for measuring blood glucose levels. Every measure-
m e n ti ss a v e di nm e m o r y ,a n df r o me ﬃciently sampled data,
Figure 7: An image shows a list-watch type noninvasive blood glu-
cose measurement [1]. The sensor can avoid damaging the tip of
a ﬁnger or earlobe to sample blood in a noninvasive way. There-
fore, it basically utilizes a quite low electric current to draw blood
glucose penetrable through the skin. This sampled glucose is aggre-
gated into a sensing part of the device integrating an electrode that
is used for measuring blood glucose levels.
the blood glucose level transitions and patterns can be com-
puted.IncaseofGlucoWatchG2Biographer,abloodglucose
reading period is adjustable in the range of 10 minutes to 13
hours [1]. Although the GlucoWatch already won FDA ap-
proval,thenoninvasivebloodglucosesensorsarestillsupple-
mental use only rather than used as the main measurements,
such as ﬁngerstick blood glucose sensors [1]. Therefore, in
case intensive measurements that pursue more accurate vi-
tal data are required, noninvasive blood glucose sensors are
used supplemental to the conventional testing results. From
the results, the best decisions are made by a physician.
5.2.4. Commercialsensors
H e r ew eu s eat a b l ea sf o l l o w st oc o m p a r eb e t w e e nf o u r
typical commercial glucose sensors (Abbott [39], MiniMed
Paradigm [40], MiniMed Guardian, [41]a n dD e x C o m[ 42])
from the following aspects: (1) accuracy of measurements,
(2) start-up time, (3) sensor lifetime (with batteries), (4)
howtheycalibratevalues,(5)howfrequentlytheydisplaythe
data, (6) memory size to store the data, (7) transmission dis-
tance (from the sensor to a monitor), (8) batteries, (9) mon-
itor size, and (10) alarm system.
5.3. Subcutaneousdevices
For the sake of the safety, currently, most of the continu-
ous blood glucose sensors being developed are designed to
be put into subcutaneous tissues. Several methods for sub-
cutaneousinjectionhavebeenproposedandimplementedin
ordertotakeadvantageofthebeneﬁtsofsubcutaneousinjec-
tion [15]. Manual injection systems typically include a sub-
cutaneous needle or injection pen, which are applied accord-
ing to a physician prescribed schedule. Continuous control
systems generally deal with its time-to-act shortfalls through
appropriate algorithms and choice of insulin.10 International Journal of Telemedicine and Applications
Table 2: Speciﬁcation comparison of commercial blood glucose sensors.
Features Abbott freestyle
navigator [39]
MiniMed
paradigm
real-time system
[40]
MiniMed
guardian real-time
system [41]
DexCom [42]
Accuracy Varies
Consensus error
grid: 98.9% A+B
mard(mean)
−19.7% (median)
−15.5%
Consensus error
grid: 98.9% A+B
mard(mean)
−19.7% (median)
−15.5%
Consensus error
grid: 95.4% A+B
mard(mean) −49%
(median) −15.9%
Startup
initiation
time
10 hours 2 hours 2 hours 2 hours
Sensor life 5-day wear
indication Above 72 hours Above 72 hours Above 72 hours
Calibration
method
Requires
calibration at 10,
12, 24, and 72
hours after the
insertion of the
sensor
Alarms when
calibration value
is not entered on
time. First and
second calibration
should be done
for 2 and 6 hours
after insertion
Alarms when
calibration value
is not entered on
time. First and
second calibration
should be done
for 2 and 6 hours
after insertion
First calibration
after 30 minutes
and then for every
12 hours. Manual
calibration is not
possible
Frequency of
display Every 1 minute Every 5 minutes Every 5 minutes Every 5 minutes
Transmitter
memory —
Yes, the
transmitter stores
missed data for up
to 40 minutes
Yes, the
transmitter stores
missed data for up
to 40 minutes
No, transmission
lost is data lost
Range of
monitor to
transmitter
10 feet 6 feet 6 feet 5 feet
Monitor
batteries
Uses 2 AAA
batteries with
replacement for
every three
months
No separate
monitor required.
Uses insulin pump
Uses 2 AAA
Batteries.
Indication is set
for chance of
battery
Uses rechargeable
batteries
Monitor size 3“× 2.5”
Separate monitor
is not available.
Uses insulin
pump for display
3“× 2.7” 3“× 2.5”
Alarms on
user-set low
and high
thresholds
Applicable Applicable Applicable Applicable
5.3.1. Open-ﬂowmicroperfusion(OFM)
In the open-ﬂow microperfusion (OFM), in order to cap-
ture the blood glucose levels subcutaneously, a needle-like
double-lumen catheter is inserted into the adipose tissue
[24]. Firstly, it is supported by a steel mandril, but eventu-
ally this steel mandril is switched by the inner cannula. In the
double-lumencatheter,aperfusionﬂuidisﬁlledintheannu-
lar space between the inner cannula and the outer catheter.
Because of partial equilibration between the interstitial ﬂuid
and the perfusate, aspiration occurs. Thus the glucose sen-
sor outside the body can capture glucose from the aspirated
ﬂuid.
In this method, since the implantable part of sensor is
just like a needle for the subcutaneous insulin injection, it is
comparatively easy for patients to insert the sensor.
Compared to actual clinical practices, where blood sam-
ples are picked from intravenous injections directly measur-
ing current blood glucose proﬁles, the subcutaneous mon-
itoring has diﬀerent results from those from the capillary
monitoring due to the ﬁrst-order lag [43]. Therefore, in the
subcutaneous monitoring, it is required to approximate ac-
tual blood glucose proﬁles from subcutaneously captured
data by ﬁnding a relation between blood and subcutaneous
glucose proﬁles. A capillary and interstitial compartment
model is shown in Figure 8.Daisuke Takahashi et al. 11
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Figure8:Acapillaryandinterstitialcompartmentalmodel[43,44].
glucose uptake, and diﬀusions between capillary and interstitial tis-
sues are represented as arrows.
To ﬁnd a mathematical relation between the blood and
subcutaneousglucoseproﬁles,[43]utilizesaﬁrst-orderlagto
describe the subcutaneous glucose dynamics in terms of the
blood CB and subcutaneous glucose proﬁles CS as follows:
dCs
dt
=−

k02 +k12

Cs +k21
V1
V2
CB,( 5 )
where k02 is an uptake rate of glucose in the subcutaneous
tissues, k12 and k21 are diﬀusion rates between the blood
and subcutaneous compartments, and V1 and V2 represent
the volumes of both blood and subcutaneous tissues, respec-
tively.
The same ﬁrst-order model for the subcutaneous glu-
cose dynamics model is derived in the paper [45], which
showed that an actual value of k12 is within the range of 0.04
to 0.11min−1.A l s o ,[ 45] ﬁgured out from rat studies that a
value of k02 is 0. Moreover, a ﬁrst-order model can be written
as
dy
dt
= ay+bu =−
1
τ
y +
k
τ
u,( 6 )
where u and y are the input and output perturbations, re-
spectively, and k and τ are the gain and time constants. Thus
comparing this standard form to an equation derived by
[43, 45], k and τ a r es o l v e da sf o l l o w s :
k =
k12
k02 +k12
, τ =
1
k02 +k12
. (7)
In [43], by setting k and τ to 1 and 12 minutes, respec-
tively,asimplesimulationmodelisgeneratedwiththereduc-
tion of blood glucose from 200 to 100mg/dl and a ﬁrst-order
decay time is 75 minutes. Subcutaneous measurement has a
noise with a standard deviation of 1mg/dl.
5.3.2. Microneedlearray
O n es u b c u t a n e o u sd e v i c et ob ep r o p o s e di sm i c r o n e e d l e s
made out of silicon [29]. Microneedles for insulin injection
are designed to penetrate through several layers of skin: the
stratus corneum layer, the epidermis layer, and part of the
r
R = 3r
Figure 9: Microneedle honeycomb formation.
dermis layer. This method of injection punctures through far
fewernervecellsthanclassicintravenousinjection, whilestill
having access to the dermis layer, which is rich in blood ves-
sels. This results in a far less invasive and painful injection
experience for the patient.
An expansion upon this idea has been to fabricate an ar-
ray of microneedles. This provides many beneﬁts, with few
disadvantages. The more microneedles used, the smaller in
diameter each needle needs to be in order to facilitate a
load-free ﬂow of insulin into the body. Shrinking the size of
the needles translates into an even less painful experience,
while maintaining the same operational insulin ﬂow rate.
Additionally, an array of needles provides redundancy to the
injection system, safeguarding against reduced ﬂow due to
channel blocking or clotting. Flow rate, Q,c a nb ef o u n da s
follows, given n needles, pressure change ΔP, needle length
L, needle radius r, and ﬂuid viscosity μ, where the relation-
ship of R and r can be found in Figure 9:
R =
8μL
πr4 ,
Q = n
ΔP
R
,
Q = nΔP

πr4
8μL

.
(8)
Note that the ﬂow rate is linearly proportional to the
number of microneedles, given a ﬁxed radius. Unfortunately,
the ﬂow also decreases by an order of 4 as radius is reduced.
Replacing a single large needle with a honeycomb forma-
tion of 7 tightly packed microneedles (each one-third of the
diameteroftheoriginalneedle)producesaﬂowofonly8.6%
of the original ﬂow for the same surface area. This observa-
tion makes evident the fact that due to the high-order im-
pact of needle radius, the skin area required for a micronee-
dle array increases exponentially as the size of the needles are
reduced. In practice, the ﬂow rate required is actually quite
low, however, making this exponentially increasing contact
area functionally negligible to the end user, due to its still
relatively small size. As far as the patient is concerned, the in-
crease in skin surface required is well worth the signiﬁcantly
reduced invasiveness and pain of the device.12 International Journal of Telemedicine and Applications
6. CONTROLLINGBLOOD GLUCOSE PROFILES
Bydeployingdevicesdescribedintheprevioussectionaswell
as understanding the mechanism of the insulin-glucose dy-
namics, blood glucose proﬁles can be controlled systemati-
cally. However, in general, not only the insulin-glucose dy-
namics but also any other human metabolism are so compli-
cated that they can be hardly quantiﬁed. Therefore, arguably,
the most complex component of blood glucose management
isthecontroldomain.Thereareseveralclassesofsolutionsto
this problem, ranging in complexity, prerequisite knowledge,
and feedback.
To do this, researchers ﬁrst empirically or with the fun-
damental methods derive a couple of mathematical equa-
tions about the insulin-glucose dynamics [46, 47]. While the
empirical methods largely depend on the input-output data
from experiments, the fundamental methods basically derive
them from the knowledge about the human internal func-
tions which are already familiar enough. After constructing
a mathematical model of the insulin-glucose dynamics, an
insulin-dependent diabetes therapy is designed. The goal of
the therapy is to mitigate the excessive glucose production
by artiﬁcially secreting exogenous insulin systematically. The
insulin secretion must follow the actual metabolic function-
ality.
Thecontrolmethodsarebroadlycategorizedinthreecat-
egories: open-loop control, closed-loop control, and partial
closed-loop control methods [15]. This section brieﬂy ex-
plains these three control methods with applications. More
detailed explanations can be found in our survey on control
methods in [5].
6.1. Open-loopcontrol
Open-loop control methods are occasionally called the pro-
grammed insulin infusion system. One type of this method is
one that was developed by Case Western Reserve University,
and this system is considered to be one of the most intelli-
gent programmed insulin infusion products that deal with
the noninsulin-dependent diabetics. The idea is that from an
analysis of the insulin curve in the nondiabetic, it was turned
out that the curve approximately traces a combination of a
double exponential curve and a basal insulin infusion [48].
According to this mathematical model, an intravenous in-
sulin delivery system was designed such that it followed the
real pancreas functionality of the nondiabetic. The system
utilized a portable cart containing the control system, the
insulin pump, power supplies, and insulin reservoir so that
the patient could move around with the devices. The insulin
pump delivers low-concentration insulin and updates the in-
sulin delivery rate every 30 seconds. Because of its simplicity,
the system can be set up and operated by nurses [48].
6.2. Closed-loopcontrol
At ﬁrst, a ﬂow of the closed-loop control scheme is shown
in Figure 10. The closed-loop system completes its operat-
ing cycle within the system and no external interaction to
diabetic patients is required [15, 24]. In other words, the
Set
position
Controller
Insulin
dosage S.C. insulin
pump Patient
Glucose S.C. glucose
measurement
Figure 10: A control ﬂow of closed-loop control models [15]. En-
tire loop of the control is closed from outside by utilizing an insulin
pumpandinvivobloodglucosesensors.Bothinsulininjectionsand
glucose measurements are carried out subcutaneously.
closed-loop control uses the feedback from the output. Typ-
ically, the closed-loop system for type 1 diabetes therapy uti-
lizes the glucose sensor and schematically consists of three
phases: blood glucose measurements, insulin demand calcu-
lation, and insulin injection. The closed-loop system repeats
this sequence.
Several papers already proposed applications and math-
ematical models to suﬃce this model. Such applications in-
clude the pole-assignment strategy, self-tuning adaptive con-
trol, model predictive control, and neural predictive control.
In short, the pole-assignment strategy calculates the in-
sulin injection rate (IIR) according to the current blood glu-
coselevelsplustrendsofthebloodglucoselevelsaswellasthe
pharmacokinetics of insulin infusion. Although the calcula-
tion is very simple, the pole-assignment strategy is time con-
suming because of repeatedly evaluating the model parame-
tersonlyfromthecurrentmeasurements.Ontheotherhand,
the self-tuning adaptive control utilizes a recursive computa-
tion of the model parameters to generate the IIR faster than
the pole-assignment strategy [15].
6.3. Partiallyclosed-loopcontrol
A ﬂow of the partially closed-loop control is shown in
Figure 11. Like the closed-loop control models, the partially
closed-loop control utilizes the external devices, such as in-
sulin pumps and blood glucose sensors. The major diﬀer-
encebetweentheclosed-loop andpartialclosed-loop control
methods is that the closed-loop control only depends on the
feedbackfromtheoutput,whilethepartialclosed-loop relies
on the physician assessment of the condition as well.
Thus in a partially closed-loop control of the insulin de-
pendentdiabetestherapy,measurementsareconductedthree
to seven times per day, and insulin injections are also per-
formed three to four times under the supervision of a physi-
cian. These decisions, for example, the number and type of
insulin injections and insulin dosage [15] ,a r em a d ea c c o r d -
ing to model-based or algorithmic-based decision support
systems, such as DIAS, AIDA, and T-IDDM [15]. Insulin
injections are usually performed by using the subcutaneous
(SC) route due to its management and safety.
For example, unlike the pole-assignment strategy or
the self-tuning adaptive control in the closed-loop control
scheme, AIDA simulates the eﬀect of the exogenous insulin
injections and virtually models insulin-glucose dynamicsDaisuke Takahashi et al. 13
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Figure 11: A control ﬂow of partially closed-loop insulin therapy
models from [15]. In general, in this case, insulin dosages are sup-
ported by an expert system that generates an optimal insulin dosage
from a comparison between a model case and a prediction of a fu-
ture blood glucose transition.
based on their physiological rules around metabolism of a
single glucose compartment rather than determining the IIR
[15, 43, 44]. According to the virtually modeled insulin-
glucose dynamics, a physician determines the appropriate
exogenous insulin injection. Likewise, DIAS is a nonlinear
model of the blood glucose-insulin system based upon real-
life parameters versus, simply, the blood glucose measure-
ments [49]. It incorporates qualitative and quantitative in-
puts from the user, including the blood glucose levels, meals,
and past insulin injections.
In addition to DIAS, AIDA, and T-IDDM, the Bergman
model and physician prescribed regiment are also catego-
rized in the partially closed-loop control models [5].
7. CONCLUSION
It is evident that reliable solutions to diabetes management
are highly sought after and researched. The health beneﬁts
associated with intensive diabetes treatment can save untold
lives and make life far more comfortable for many others.
Additionally, with the number of diabetes suﬀerers increas-
ing annually, and the disease already costing well over $100
million per year in health care expenses, it is a very lucrative
market. Eﬀective solutions can help mitigate and control the
eﬀects and tolls of diabetes in terms of both health and eco-
nomic impact.
Personal artiﬁcial pancreas devices are coming into
greater use, spurred on by improvements in technology and
an increasing demand. Appropriate technologies must be
developed and exploited in order to improve upon today’s
methods. Increased miniaturization of sensors, pump, and
controls continuously improve the portability of personal
continuous control devices, thereby increasing their ubiquity
among insulin-dependent diabetes patients.
This paper summarizes diabetes and its therapies. Cur-
rently, diabetes is considered not to be cured by any medical
treatment.However, since the Diabetes Control andCompli-
cation Trial demonstrated that, by well-controlling, the glu-
cose metabolism for the diabetic, especially type 1 diabetes
patients, expected emergence of complications can be de-
layed or protected, several techniques to replace exogenous
insulin to the lack of endogenous insulin in order to suppress
theriseoftheamountofglucoseinbloodaredeveloped,that
is, the insulin-dependent diabetes therapy.
Besides, to support the insulin therapy, several medical
devices concerning diabetes are being developed. Examples
of these devices are insulin pumps and blood glucose sen-
sors. In this paper, a couple of examples of insulin pumps
and blood glucose sensors are presented. Especially, in blood
glucose sensors, three types of them are briefed: the ﬁnger-
stick meter reading, in vivo, and the noninvasive blood glu-
cose measurement, and each of them has its advantages and
disadvantages.Forexample,although,iftheyareavailable,in
a long time period, the in vivo blood glucose sensors largely
beneﬁt for modeling the blood glucose transitions and con-
sequently beneﬁt for the insulin therapy, they are only ap-
proved for a short time use currently, for example, only a 3-
day use is approved by U.S. Food and Drug Administration
(FDA). The insulin therapy using the in vivo sensors and in-
sulin pumps are usually called the closed-loop control.
In conclusion, in the near future, several research inten-
tions will be considered. The ﬁrst is the early development
of long-term available in vivo blood glucose sensors. There
is no explanation about this direction because it is believed
that the emergence of long-term in vivo sensors should en-
hancethebloodglucosemeasurementandconsequentlyease
the predictions and plans for the insulin therapies to avoid
both hyper- and hypoglycemia. The second is the develop-
ment of a more accurate but simpler mathematical model
for the insulin-glucose dynamics. This direction will also en-
hance the insulin therapy largely in the diabetic treatment
by partially closed-loop control. For more details about the
control theory in diabetes, please refer to our survey paper
in control methods [5]. In addition to these two directions,
the paper [15] points out two more directions: one is the de-
velopment of decision support systems, and the other is the
developmentofthenoninvasivebloodglucosemeasurement.
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